1. Home
  2. CHRS vs FTRK Comparison

CHRS vs FTRK Comparison

Compare CHRS & FTRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • FTRK
  • Stock Information
  • Founded
  • CHRS 2010
  • FTRK 2012
  • Country
  • CHRS United States
  • FTRK Singapore
  • Employees
  • CHRS N/A
  • FTRK N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • FTRK
  • Sector
  • CHRS Health Care
  • FTRK
  • Exchange
  • CHRS Nasdaq
  • FTRK NYSE
  • Market Cap
  • CHRS 112.5M
  • FTRK 102.2M
  • IPO Year
  • CHRS 2014
  • FTRK 2025
  • Fundamental
  • Price
  • CHRS $0.76
  • FTRK $4.58
  • Analyst Decision
  • CHRS Buy
  • FTRK
  • Analyst Count
  • CHRS 3
  • FTRK 0
  • Target Price
  • CHRS $4.68
  • FTRK N/A
  • AVG Volume (30 Days)
  • CHRS 1.2M
  • FTRK 2.0M
  • Earning Date
  • CHRS 08-07-2025
  • FTRK 01-01-0001
  • Dividend Yield
  • CHRS N/A
  • FTRK N/A
  • EPS Growth
  • CHRS N/A
  • FTRK N/A
  • EPS
  • CHRS N/A
  • FTRK N/A
  • Revenue
  • CHRS $272,251,000.00
  • FTRK $117,230.00
  • Revenue This Year
  • CHRS N/A
  • FTRK N/A
  • Revenue Next Year
  • CHRS $132.69
  • FTRK N/A
  • P/E Ratio
  • CHRS $1.79
  • FTRK N/A
  • Revenue Growth
  • CHRS 19.87
  • FTRK 2589.48
  • 52 Week Low
  • CHRS $0.66
  • FTRK $3.15
  • 52 Week High
  • CHRS $2.43
  • FTRK $9.69
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 40.42
  • FTRK N/A
  • Support Level
  • CHRS $0.74
  • FTRK N/A
  • Resistance Level
  • CHRS $0.90
  • FTRK N/A
  • Average True Range (ATR)
  • CHRS 0.05
  • FTRK 0.00
  • MACD
  • CHRS 0.01
  • FTRK 0.00
  • Stochastic Oscillator
  • CHRS 13.56
  • FTRK 0.00

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About FTRK FAST TRACK GROUP

Fast Track Group is a regional entertainment-focused event management and marketing company that provides a full range of services including experiential marketing, artiste endorsement and management, movie premiere organizations, grand openings, and concerts. It also creates, develops, organizes, hosts, and manages various events and concerts.

Share on Social Networks: